To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans
Launched by GOOD FOOD PRACTICE, SWEDEN · Dec 15, 2009
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
This study is the first to investigate the relative colonisation of the human GI tract by L Reuteri ATCC PTA 4659. Simple demonstration that they survive passage is the first step in development of potential new probiotics, which is necessary before these strains can be considered for continued testing in probiotic food matrices. The aim of this study will evaluate the safety and tolerability of Lactobacillus Reuteri in healthy adult subjects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males and females
- • Age 18-65 years
- • BMI 19-33
- • Hb 120 g/women 130 g/l for men
- • Healthy assessed by screening tests and physical examination
- • Signed informed consent and bio bank consent
- Exclusion Criteria:
- • Participation in a clinical study within 90 days prior screening use of antibiotics 2 weeks before baseline
- • Pregnant or lactating
About Good Food Practice, Sweden
Good Food Practice, based in Sweden, is a clinical trial sponsor dedicated to advancing nutritional science and promoting health through innovative food solutions. With a strong emphasis on rigorous research methodologies and ethical standards, the organization conducts clinical trials aimed at evaluating the efficacy and safety of novel food products and dietary interventions. Committed to enhancing public health, Good Food Practice collaborates with leading researchers and institutions to ensure that its studies contribute valuable insights to the fields of nutrition and wellness, ultimately fostering healthier lifestyles for individuals and communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Uppsala, , Sweden
Patients applied
Trial Officials
Birgitta E Sundberg, PhD
Principal Investigator
Good Food Practice, Uppsala, Sweden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials